Unveiling Lp(a)

Step 1
Step 2
Step 3
Step 4
Post Test
Step 5
Step 6

Activity Title: Unveiling Lipoprotein(a): Hidden Culprit in Cardiovascular Disease

The National Lipid Association (NLA) hosted a Continuing Medical Education/Continuing Education (CME/CE) Symposium on September 8, 2023, as part of our Fall Clinical Lipid Update. This symposium, titled "Unveiling Lipoprotein(a): Hidden Culprit in Cardiovascular Disease," was designed to address critical topics related to Lipoprotein(a) (Lp(a)), including the importance of standard measurements for Lp(a), exploring different management techniques in patients with elevated Lp(a), and understanding the impact of population differences on Lp(a) levels.

October 18, 2023

October 18, 2024

Internet Enduring Activity

This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, advance practice registered nurses, nurse practitioners and registered dietitians seeking to develop an expertise in clinical Lipidology.

At the Conclusion of this activity, participants should be able to:

  • Discuss the role of lipoprotein(a) (Lp(a)) in risk assessment and management of cardiovascular disease (CVD).
  • Assess the potential of new and emerging therapeutic options to manage Lp(a).
  • Identify risk enhancing factors that might impact the care of patients with elevated Lp(a).
  • Recognize population differences that may impact clinical care.

Statements of credit will be awarded based on the participant's completion and submission of the activity evaluation form. A statement of credit will be available for download upon completion of the online evaluation form. To receive credit, participants should complete the online course, score at least 30% on the post-test, and submit the evaluation. The deadline to claim credit is October 18, 2024.

Questions about this CME activity may be sent to the National Lipid Association’s Continuing Medical Education Department at cme@lipid.org.

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

*IMPORTANT* Pharmacists MUST request credit before October 18, 2024. Credit requested after this date will be subject to a fee by the accreditation board.

This activity is supported by educational funding provided by Novartis.

ABIM Logo Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Joint Accreditation Provider Logo CME credit provided by the National Lipid Association
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

Physician Credit Designation Statement
The National Lipid Association designates this enduring internet activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.

Universal Activity Number – JA0007192-0000-23-044-H01-P (Application)
This Activity has been approved for 1.25 contact hour(s) (.125CEUs) of the Accreditation Council for Pharmacy Education.

The maximum number of hours awarded for this CE activity is 1.25 contact hours.

This continuing education activity offers .25 pharmacotherapy contact hours


Marlys L. Koschinsky, PhD
Scientist, Robarts Research Institute
Professor, Dept. of Physiology & Pharmacology
Schulich School of Medicine & Dentistry
The University of Wester Ontario
London, Ontario, Canada

Michael D. Shapiro, DO, MCR, FNLA*
Fred M. Parrish Professor of Cardiology and Molecular Medicine
Director, Center for Prevention of Cardiovascular Disease
Section on Cardiovascular Medicine
Wake Forest University School of Medicine
Winston Salem, NC
Christie M. Ballantyne, MD, FNLA
President-Elect, National Lipid Association
Chief, Section of Cardiovascular Research
Director, Center for Cardiometabolic Disease Prevention
Professor of Medicine, Molecular and Human Genetics, and Integrative Physiology
Baylor College of Medicine
Houston, TX
Calvin Yeang, MD, PhD
Assistant Professor of Clinical Medicine
University of California San Diego
San Diego, CA
Name Relationship Company
Christie M Ballantyne, MD Consultant 89Bio, Abbot Diagnostic, Alnylam Pharmaceuticals, Althera, Amarin, Amgen, Arrowhead, AstraZeneca, Denka Seiken, Esperion, Genentech, Gilead, Illumina, Ionis, Matinas BioPharma Inc, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic
Contracted Research Abbot Diagnostic, Akcea, Amgen, Arrowhead, Esperion, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic
Michael D. Shapiro, DO, MCR Consultant Novartis, Ionis, Regeneron, Emendo Bio
Advisory Board Amgen, Novartis, Ionis, Novo Nordisk, Esperion, Precision BioSciences
Calvin Yeang, MD, PhD Consultant Kaneka, Ionis
Contracted Research Arcturus Therapeutics, Arnatar Therapeutics
Marlys L. Koschinsky, PhD N/A Nothing to disclose.
Name Relationship Company
NLA N/A The National Lipid Association Staff has nothing to disclose.

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME. All disclosures have been reviewed and resolved at this time.

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

Publish Date: 
Wednesday, October 11, 2023 - 11:45

This page was last updated: Oct 11, 2023